Relevant bibliographies by topics / Mycosis - Treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Mycosis - Treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mycosis - Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Mycosis - Treatment"

1

Sakaniya, L. R., and I. M. Korsunskaya. "Foot mycosis: how to help active patients." Meditsinskiy sovet = Medical Council, no. 12 (October 7, 2020): 24–27. http://dx.doi.org/10.21518/2079-701x-2020-12-24-27.

Full text
Abstract:
Mycotic infections of the feet are common fungal infections in our time. According to some reports, about 10% of the world's population suffer from these infections. Men suffer from foot mycosis more often than others. Foot mycosis can manifest itself in three clinical forms: interdigital, plantar and vesiculopapular. Foot mycosis is often combined with onychomycosis or becomes a risk factor for its development. Many diseases, such as diabetes mellitus, vascular diseases, obesity are risk factors for foot mycosis. But what is important is that young and middle-aged people who lead an active lifestyle are at risk. It has long been established that public places such as gyms, swimming pools, baths and saunas are a source of mycotic infections. The internal climatic environment of footwear also has a significant impact on the development of foot mycosis. Closed shoes with high internal temperature and humidity create ideal conditions for dermatophyte growth. That is why people who prefer closed, even cloth shoes, or office workers, who are forced to constantly wear closed shoes, often suffer from foot mycosis and other fungal infections.The main problem in the treatment of foot mycoses is adherence to the prescribed treatment. In our practice, mycotic lesions are more common in people who lead an active lifestyle and are unable to adhere to a long course of therapy. Indeed, the treatment of mycosis often involves a two-week application of some topical antifungal agent. It is optimal to prescribe a single application of terbinafine film forming solution to such patients. This drug ensures the clinical effectiveness of therapy as it keeps antifungi-cidal activity for 13 days from the date of application and high adherence to treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

Yakovlev, A. В. "Issues of stage-by-stage approach to the external therapy of foot skin mycosis." Medical Council, no. 21 (January 20, 2019): 146–51. http://dx.doi.org/10.21518/2079-701x-2018-21-146-151.

Full text
Abstract:
Foot skin mycosis is one of the most topical problems in dermatovenerology due to the extreme prevalence of these diseases. Treatment of foot skin mycoses is the most important step in the prevention of onychomycosis. The tactics and a specific sequence of the external therapy depends on the specific clinical form of mycosis: acute inflammatory forms require the prescription of solutions and gels, subacute forms required creams, chronic forms require adhesive agents. Exudative form of the foot skin mycosis with vesiculation is an indication for the combination therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Ghitea, Timea Claudia, Simona Bungau, Delia Mirela Tit, Lavinia Purza, Pavel Otrisal, Lotfi Aleya, Gabriela Cioca, Carmen Pantis, and Liviu Lazar. "The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome." Revista de Chimie 71, no. 1 (February 7, 2020): 335–41. http://dx.doi.org/10.37358/rc.20.1.7854.

Full text
Abstract:
This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially evaluated at 10 days after the begining of the treatment (to track mycotic disease evolution in the acute phase), at 60 days (to evaluate the recurrence of mycoses) and at 180 days to track recurrent disease. Most infections were acute (77.78%), the chronic ones representing only 5.56% of cases. There were also 12 cases with recurrent infections (16.67%), out of which 6 cases (8.33%) had previously shown resistance to Nystatin. In the 72 cases there was a sensitivity of 100.00% for oregano oil and Ketaconazolum, insignificantly higher than for Myconazolum (97.22%, p=0.157), but significantly higher than for Clotrimazolum and Nystatinum (94.44%, p=0.0437), Variconazole and Fluconazole (88.89%, p=0.0038) and Itraconazole (86.11%, p=0.0011). The results of this study showed an increased efficiency of oregano oil on the symptomatic and paraclinical improvement of mycotic infections in the study, both on short term and on long term, which was completed with high tolerability.
APA, Harvard, Vancouver, ISO, and other styles
4

Vdovina, L. V., N. V. Tiunova, S. M. Tolmacheva, and I. N. Usmanova. "Geotrlchous stomatitis in the dental practice." Endodontics Today 18, no. 2 (August 1, 2020): 68–72. http://dx.doi.org/10.36377/1683-2981-2020-18-2-68-72.

Full text
Abstract:
A literature review was conducted on rare mycoses of the oral mucosa in patients with immunode^ciency conditions and hematologic malignant diseases, in particular, etiopathogenetic aspects, clinical features and an approach to the treatment of rare oral mycosis - geotrlchous stomatitis were examined.
APA, Harvard, Vancouver, ISO, and other styles
5

Mizernitsky, Yu L., S. E. Dyakova, M. V. Kostyuchenko, G. A. Klyasova, A. A. Malchikova, and M. P. Afanasyeva. "Allergic bronchopulmonary mycosis in a child caused by Paecilomyces lilacinus." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 64, no. 2 (May 15, 2019): 102–9. http://dx.doi.org/10.21508/1027-4065-2019-64-2-102-109.

Full text
Abstract:
The article discusses the problem of allergic bronchopulmonary mycoses, which occur in children much more often than they are diagnosed. Their treatment is a challenge, and the prognosis is very problematic. In addition to the most frequent cause of Aspergillus, allergic bronchopulmonary mycoses can be caused by various fungi. The clinical example demonstrates the difficulty of diagnosing and treating a child with allergic bronchopulmonary mycosis caused by a rare type of filamentous fungi Paecilomyces lilacinus.
APA, Harvard, Vancouver, ISO, and other styles
6

Shurygin, A. A., A. E. Shirinkina, E. A. Makarova, A. V. Sergeev, and I. A. Marusich. "Clinical case of invasive candidiasis in phthisiatrician’s practice." Perm Medical Journal 36, no. 6 (January 30, 2020): 83–94. http://dx.doi.org/10.17816/pmj36683-94.

Full text
Abstract:
The paper presents a case of generalized candidomycosis in a 67-year old woman. Literature data regarding the cases of respiratory mycoses and candida sepsis are summarized. This case is interesting from the point of view of difficulty of differential diagnosis in patients with respiratory mycosis and tuberculosis, choice of adequate treatment.
APA, Harvard, Vancouver, ISO, and other styles
7

Edakuni, Setsuo, Ryozo Hayasida, Akihiro Hayashi, Akira Adachi, Yutaka Nishimura, Teruo Kakegawa, and Shinzo Edakuni. "Surgical Treatment of Pulmonary Mycosis." Journal of the Japanese Association for Chest Surgery 4, no. 3 (1990): 318–24. http://dx.doi.org/10.2995/jacsurg1987.4.318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Acikgoz, Gurol, Yildiray Yeniay, Ercan Caliskan, and Osman Kose. "Bexarotene Treatment for Mycosis Fungoides." Gulhane Medical Journal 57, no. 4 (2015): 343. http://dx.doi.org/10.5455/gulhane.159145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

CHURCH, SALLY, G. WYN-JONES, A. H. PARKS, and H. E. RITCHIE. "Treatment of guttural pouch mycosis." Equine Veterinary Journal 18, no. 5 (September 1986): 362–65. http://dx.doi.org/10.1111/j.2042-3306.1986.tb03654.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Freiman, Anatoli, and Denis Sasseville. "Treatment of Mycosis Fungoides: Overview." Journal of Cutaneous Medicine and Surgery 10, no. 5 (September 2006): 228–33. http://dx.doi.org/10.2310/7750.2006.00051.

Full text
Abstract:
Background: Mycosis fungoides (MF) is the most common clinicopathologic subtype of primary cutaneous T-cell lymphoma. Objective: The therapy of MF is highlighted in this overview. Results and Conclusions: Skin-directed MF therapies include topical corticosteroids, nitrogen mustard, carmustine (BCNU), topical bexarotene gel, imiquimod cream, radiotherapy, total skin electron beam therapy, and phototherapy. Systemic therapies include extracorporeal photopheresis, interferon, oral bexarotene, denileukin diftitox, monoclonal antibodies and cytokine therapy, and other systemic chemotherapy. Finally, some investigative therapeutic modalities are presented.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Mycosis - Treatment"

1

Carvalho, Fabiana Moura de. "Avaliação da associação sulfametoxazol-trimetropim no tratamento da paracoccidioidomicose experimental murina /." Botucatu : [s.n.], 2006. http://hdl.handle.net/11449/106361.

Full text
Abstract:
Orientador: Rinaldo Poncio Mendes
Banca: Eva Burger
Banca: Roberto Martinez
Resumo: O tratamento da PCM, micose sistêmica causada Paracoccidioides brasiliensis, continua sendo objeto de pesquisa clínica e experimental. Este trabalho avaliou a eficácia de diferentes esquemas terapêuticos com cotrimoxazol (CMX), na dose diária de 200 mg/kg de peso corporal, em dose diária única, no tratamento da PCM murina. Os resultados revelaram que o tratamento com CMX por tempo prolongado foi eficaz quando iniciado precoce ou tardiamente. O tratamento com curta duração foi ineficaz, pois não determinou diminuição da carga fúngica, durante as 20 semanas de seguimento. O efeito do CMX foi o mesmo em pulmões e baço, nos diferentes esquemas terapêuticos utilizados, eficazes ou não. A mortalidade cumulativa entre os grupos 1, 2 e 4 não diferiram entre si, os grupos 3 e 5 apresentaram a melhor taxa de sobrevida. Os níveis séricos de anticorpos específicos foram detectados a partir da segunda semana, apresentando maiores índices nos animais do G2, sendo que nesses os níveis aumentaram até a oitava semana e permanecendo estáveis por todo o experimento. No G3 houve uma flutuação durante todo o experimento apresentando níveis altos na 20a semana. Os grupos 4 e 5 permaneceram estáveis durante todo o experimento. Os efeitos benéficos do tratamento foram observados com a administração de CMX em dose única diária, cujos níveis séricos se mantiveram adequados por menos de 12 horas. Esses resultados, bastante satisfatórios, demonstram que o modelo experimental murino é bom método de avaliação da eficácia do CMX no tratamento da PCM e sugerem a avaliação de outros esquemas terapêuticos, como a administração a cada 12 horas.
Abstract: Paracoccidioidomicosis (PCM) treatment, a systemic mycosis caused by Paracoccidioides brasiliensis, has been a clinical and experimental research issue. This work evaluated the efficacy of different therapeutic protocols with cotrimoxazole (CMX) on a daily dosage of 200mg/kg body weight, in a single daily dosage on murine PCM treatment. The results showed that CMX treatment for a prolonged period was efficient when started early or late. The short duration treatment was inefficient once it did not determine fungus load decrease during 20 weeks of following. CMX effect was the same in lungs and spleen under different therapeutic protocols used, whether efficient or not. Cumulative death tends to be different among studied groups. Death frequency was smaller in prolonged treated groups with an early or late protocol starting. Specific antibodies blood levels were detected from the second week and did not differ among experimental groups. Beneficial effects of treatment were observed with CMX administration on a daily single dosage and blood levels remained satisfactory for less than 12 hours. These results, quite satisfactory, show that murine experimental protocol is a good evaluation method of MCX effectiveness on PCM treatment and it suggests the evaluation of other therapeutic protocols, as an administration at every 12 hours.
Doutor
APA, Harvard, Vancouver, ISO, and other styles
2

Carvalho, Fabiana Moura de [UNESP]. "Avaliação da associação sulfametoxazol-trimetropim no tratamento da paracoccidioidomicose experimental murina." Universidade Estadual Paulista (UNESP), 2006. http://hdl.handle.net/11449/106361.

Full text
Abstract:
Made available in DSpace on 2014-06-11T19:35:39Z (GMT). No. of bitstreams: 0 Previous issue date: 2006-11-28Bitstream added on 2014-06-13T19:24:57Z : No. of bitstreams: 1 carvalho_fm_me_botfm.pdf: 667343 bytes, checksum: cf2805112d3bb1292cba3553dd03ef7c (MD5)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Universidade Estadual Paulista (UNESP)
Gap
O tratamento da PCM, micose sistêmica causada Paracoccidioides brasiliensis, continua sendo objeto de pesquisa clínica e experimental. Este trabalho avaliou a eficácia de diferentes esquemas terapêuticos com cotrimoxazol (CMX), na dose diária de 200 mg/kg de peso corporal, em dose diária única, no tratamento da PCM murina. Os resultados revelaram que o tratamento com CMX por tempo prolongado foi eficaz quando iniciado precoce ou tardiamente. O tratamento com curta duração foi ineficaz, pois não determinou diminuição da carga fúngica, durante as 20 semanas de seguimento. O efeito do CMX foi o mesmo em pulmões e baço, nos diferentes esquemas terapêuticos utilizados, eficazes ou não. A mortalidade cumulativa entre os grupos 1, 2 e 4 não diferiram entre si, os grupos 3 e 5 apresentaram a melhor taxa de sobrevida. Os níveis séricos de anticorpos específicos foram detectados a partir da segunda semana, apresentando maiores índices nos animais do G2, sendo que nesses os níveis aumentaram até a oitava semana e permanecendo estáveis por todo o experimento. No G3 houve uma flutuação durante todo o experimento apresentando níveis altos na 20a semana. Os grupos 4 e 5 permaneceram estáveis durante todo o experimento. Os efeitos benéficos do tratamento foram observados com a administração de CMX em dose única diária, cujos níveis séricos se mantiveram adequados por menos de 12 horas. Esses resultados, bastante satisfatórios, demonstram que o modelo experimental murino é bom método de avaliação da eficácia do CMX no tratamento da PCM e sugerem a avaliação de outros esquemas terapêuticos, como a administração a cada 12 horas.
Paracoccidioidomicosis (PCM) treatment, a systemic mycosis caused by Paracoccidioides brasiliensis, has been a clinical and experimental research issue. This work evaluated the efficacy of different therapeutic protocols with cotrimoxazole (CMX) on a daily dosage of 200mg/kg body weight, in a single daily dosage on murine PCM treatment. The results showed that CMX treatment for a prolonged period was efficient when started early or late. The short duration treatment was inefficient once it did not determine fungus load decrease during 20 weeks of following. CMX effect was the same in lungs and spleen under different therapeutic protocols used, whether efficient or not. Cumulative death tends to be different among studied groups. Death frequency was smaller in prolonged treated groups with an early or late protocol starting. Specific antibodies blood levels were detected from the second week and did not differ among experimental groups. Beneficial effects of treatment were observed with CMX administration on a daily single dosage and blood levels remained satisfactory for less than 12 hours. These results, quite satisfactory, show that murine experimental protocol is a good evaluation method of MCX effectiveness on PCM treatment and it suggests the evaluation of other therapeutic protocols, as an administration at every 12 hours.
APA, Harvard, Vancouver, ISO, and other styles
3

Lam, M. F., and 林文輝. "Meta-analysis of different anti-fungal prophylactic treatments in neutropenic patients." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B3197062X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lam, M. F. "Meta-analysis of different anti-fungal prophylactic treatments in neutropenic patients." Click to view the E-thesis via HKUTO, 2002. http://sunzi.lib.hku.hk/hkuto/record/B3197062X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhao, Huifang. "Improved Methods of Sepsis Case Identification and the Effects of Treatment with Low Dose Steroids: A Dissertation." eScholarship@UMMS, 2011. https://escholarship.umassmed.edu/gsbs_diss/529.

Full text
Abstract:
Sepsis is the leading cause of death among critically ill patients and the 10th most common cause of death overall in the United States. The mortality rates increase with severity of the disease, ranging from 15% for sepsis to 60% for septic shock. Patient with sepsis can present varied clinical symptoms depending on the personal predisposition, causal microorganism, organ system involved, and disease severity. To facilitate sepsis diagnosis, the first sepsis consensus definitions was published in 1991 and then updated in 2001. Early recognition of a sepsis patient followed with timely and appropriate treatment and management strategies have been shown to significantly reduce sepsis-related mortality, and allows care to be provided at lower costs. Despite the rapid progress in the knowledge of pathophysiological mechanisms of sepsis and its treatment in the last two decades, identifying patient with sepsis and therapeutic approaches to sepsis and its complications remains challenging to critical care clinicians. Hence, the objectives of this thesis were to 1) evaluate the test characteristics of the two sepsis consensus definitions and delineate the differences in patient profile among patients meeting or not meeting sepsis definitions; 2) determine the relationship between the changes in several physiological parameters before sepsis onset and sepsis, and to determine whether these parameters could be used to identify sepsis in critically ill adults; 3) evaluate the effect of corticosteroids therapy on patient mortality. Data used in this thesis were prospectively collected from an electronic medical record system for all the adult patients admitted into the seven critical care units (ICUs) in a tertiary medical center. Besides analyzing data at the ICU stay level, we investigated patient information in various time frames, including 24-hour, 12-hour, and 6-hour time windows. In the first study of this thesis, the 1991 sepsis definition was found to have a high sensitivity of 94.6%, but a low specificity of 61.0%. The 2001 sepsis definition had a slightly increased sensitivity but a decreased specificity, which was 96.9% and 58.3%, respectively. The areas under the ROC curve for the two consensus definitions were similar, but less than optimal. The sensitivity and area under the ROC curve of both definitions were lower at the 24-hour time window level than those of the unit stay level, though the specificity increased slightly. At the time window level, the 1991 definitions performed slightly better than the 2001 definition. In the second study, minimum systolic blood pressure performed the best, followed by maximum respiratory rate in discriminating sepsis patients from SIRS patients. Maximum heart rate and maximum respiratory rate can differentiate sepsis patients from non-SIRS patients fairly well. The area under ROC of the combination of five physiological parameters was 0.74 and 0.90 for comparing sepsis to non-infectious SIRS patients and comparing sepsis to non-SIRS patients, respectively. Parameters typically performed better in 24-hour windows compared to 6-hour or 12-hour windows. In the third study, significantly increased hospital mortality and ICU mortality were observed in the group treated with low-dose corticosteroids than the control group based on the propensity score matched comparisons, and multivariate logistic regression analyses after adjustment for propensity score alone, covariates, or propensity score (in deciles) and covariates. This thesis advances the existing knowledge by systemically evaluating the test characteristics for the 1991 and 2001 sepsis consensus definitions, delineating physiological signs and symptoms of deterioration in the preceding 24 hours prior to sepsis onset, assessing the prediction performances of single or combined physiological parameters, and examining the use of corticosteroids treatment and survival among septic shock patients. In addition, this thesis sets an innovative example on how to use data from electronic medical records as these surveillance systems are becoming increasingly popular. The results of these studies suggest that a more parsimonious set of definitional criteria for sepsis diagnosis are needed to improve sepsis case identification. In addition, continuously monitored physiological parameters could help to identify patients who show signs of deterioration prior to developing sepsis. Last but not least, caution should be used when considering a recommendation on the use of low dose corticosteroids in clinical practice guidelines for the management of sepsis.
APA, Harvard, Vancouver, ISO, and other styles
6

Mashao, Mmbangiseni Beauty. "Prevalence and molecular identification of candida oral infections in HIV patients attending treatment centres, Vhembe District, Limpopo Province." Diss., 2014. http://hdl.handle.net/11602/166.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Mycosis - Treatment"

1

Hospenthal, Duane R., and Michael G. Rinaldi, eds. Diagnosis and Treatment of Human Mycoses. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-325-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Feigenbaum, Ernest. Debridement and other treatment of mycotic toenails. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Health, National Center for Health Services Research and Health Care Technology Assessment, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

FRCPath, Jones Brian L., and Rautemaa Riina, eds. Therapeutic guidelines in systemic fungal infections. 4th ed. London: Remedica, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Buddle, J. R. Bacterial and fungal diseases of pigs. Canberra: Australian Govt. Pub. Service, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hall, Gerri S. Interactions of yeasts, moulds, and antifungal agents: How to detect resistance. New York: Humana Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Interactions of yeasts, moulds, and antifungal agents: How to detect resistance. New York: Humana Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

The Treatment of Mycosis with Imidazole Derivatives. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sokol, Lubomir. Mycosis Fungoides and Sézary Syndrome: Pathogenesis, Diagnosis and Treatment. Edited by Xiaohui Zhang. Nova Science Publishers, 2021. http://dx.doi.org/10.52305/lfse9103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

R, Hospenthal Duane, and Rinaldi Michael G, eds. Diagnosis and treatment of human mycoses. Totowa, N.J: Humana, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

(Editor), Duane R. Hospenthal, and Michael G. Rinaldi (Editor), eds. Diagnosis and Treatment of Human Mycoses (Infectious Disease). Humana Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Mycosis - Treatment"

1

Khan Mohammad Beigi, Pooya. "Treatment." In Clinician's Guide to Mycosis Fungoides, 23–34. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-47907-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Khan Mohammad Beigi, Pooya. "Treatment Plan." In Clinician's Guide to Mycosis Fungoides, 53–55. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-47907-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Querfeld, Christiane, Jasmine Zain, and Steven T. Rosen. "Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome." In Cancer Treatment and Research, 225–48. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-99716-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hogan, Daniel F. "Treatment of Hemorrhage Associated with Guttural Pouch Mycosis." In Advances in Equine Upper Respiratory Surgery, 249–54. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118834183.ch38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Verma, Kaushal K., and Dillip K. Parida. "Radiation Treatment of Cutaneous Lymphomas (Mycosis Fungoides) — The Indian Experience." In Radiation Treatment and Radiation Reactions in Dermatology, 109–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18830-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shi, Weiyun, and Hua Gao. "Diagnosis and Treatment of Fungal Keratitis." In Mycotic Keratitis, 79–111. Boca Raton, FL : CRC Press, Taylor & Francis Group, [2018] | “A: CRC Press, 2019. http://dx.doi.org/10.1201/9780429021473-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Just, G., D. Steinheimer, M. Schnellbach, C. Böttinger, E. B. Helm, and W. Stille. "Treatment of Candidosis in AIDS Patients." In Mycoses in AIDS Patients, 279–85. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0655-9_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Degreef, H. "Treatment of Dermatomycosis in AIDS Patients." In Mycoses in AIDS Patients, 325–28. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0655-9_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sharma, Bhavana, Payal Gupta, Prashant Borde, Arjun Ravi, and R. B. Vajpayee. "Novel Perspectives in Treatment of Fungal Keratitis." In Mycotic Keratitis, 177–88. Boca Raton, FL : CRC Press, Taylor & Francis Group, [2018] | “A: CRC Press, 2019. http://dx.doi.org/10.1201/9780429021473-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shi, Weiyun, and Hua Gao. "Special Cases in the Diagnosis and Treatment of Fungal Keratitis." In Mycotic Keratitis, 56–78. Boca Raton, FL : CRC Press, Taylor & Francis Group, [2018] | “A: CRC Press, 2019. http://dx.doi.org/10.1201/9780429021473-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Mycosis - Treatment"

1

Sygaieva, Iryna. "Mycosis induced asthma treatment: fluticasone/salmeterol vs. budesonide/formoterol reinforced by montelukast." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

González, M. A. Pagnan, J. O. Hernández Oviedo, E. Mitsoura, and D. R. Ruesga Vázquez. "Characterization of unconventional electron fields for the treatment of mycosis fungoides using the total skin irradiation technique." In XIII MEXICAN SYMPOSIUM ON MEDICAL PHYSICS. AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4901368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Varfolomeeva, E. A., G. V. Mitina, and A. A. Choglokova. "Field test of the spores of entomopathogenic fungi Lecanicillium muscarium against Adelges on conifers of the Botanical Garden of Peter the Great." In РАЦИОНАЛЬНОЕ ИСПОЛЬЗОВАНИЕ ПРИРОДНЫХ РЕСУРСОВ В АГРОЦЕНОЗАХ. Federal State Budget Scientific Institution “Research Institute of Agriculture of Crimea”, 2020. http://dx.doi.org/10.33952/2542-0720-15.05.2020.06.

Full text
Abstract:
Adelgids are dangerous sucking pests of the conifers. Adelges pectinatae pectinatae and Pineus cembrae (Cholodkovsky, 1888) are noted throughout the Botanical Garden of Peter the Great on the conifers Abies sibirica, Pinus sibirica, and Pinus Banksiana. The application of entomopathogenic fungi that can penetrate into the galls of adelgids allows decreasing the usage of the chemical pesticides. Strain G-033 VIZR, which is effective against sucking insects and mites, was examined. Conifers infected by the adelgids were sprayed with the blastospore suspension (titer – 5x107 spores/ml). The number of Adelges galls was counted before treatment and weekly for a month. The effectiveness of spores on the 7th and 10th day was 20-44 %; the effectiveness of the chemical insecticide Actara was 52-99 %. By the end of the observations, the effectiveness of the biolpesticide reached 92-98% at all species of trees and was at the level of the chemical reference. The effect of the application of spores was registered over the next month. The ability of L. muscarium to cause mycosis was proved by isolating strain G-033 VIZR from the galls of Adelges infected by fungus. The strain G-033 VIZR of L. muscarium showed high efficiency and a prolonged effect on the Adelgids population of two species A. pectinatae pectinatae and P. cembrae.
APA, Harvard, Vancouver, ISO, and other styles
4

Siddique, A., P. Nguyen, A. Zeglen, R. Z. Abraham, M. Phillips, and N. Chandan. "The Temporal Profile of a Mycotic Aneurysm - Approaches to the Treatment and Beyond." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Mycosis - Treatment' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography